Patients with CAD and clinical symptoms of heart failure or patients with suspected heart
failure with preserved ejection fraction (HFpEF) will be enrolled. Study drug will be given
as continuous IV infusion followed by oral treatment for 13 days. LV pressures and
hemodynamic data will be measured prior to and after administration of study drug. In
addition, Doppler ECHO, cardiopulmonary exercise testing (CPET), and NT-pro-BNP determination
will be performed. Adverse events and safety labs will be collected and monitored.